| Name | Title | Contact Details |
|---|
Integrated Medical Management is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RainDance Technologies, Inc. provides microdroplet-based solutions for single molecule and single cell analysis in the life sciences industry. The company’s RainStorm technology generates various discrete droplets that can encapsulate a single molecule, single cell, or reaction. It offers RDT 1000, a solution that amplifies genomic loci and leverages the sensitivity and specificity of polymerase chain reaction methodology; and ThunderStorm System, a fully automated high-throughput targeted sequencing solution that enables researchers to determine all variation contained in any region of the genome. The company also provides research screening panels, including ASDSeq for autism spectrum disorder research; XSeq for human X-chromosome research; and HLASeq for human leukocyte antigen and major histocompatibility complex research. In addition, it offers sequence enrichment consumables kits that comprise reagents and consumables, and custom-order libraries; and RainDrop Digital PCR System that transforms the performance of molecular assays by enabling digital answers across various applications, including tumor allele detection, gene expression, copy number variation, and SNP measurement. Further, the company provides remote and onsite response for various emergency repairs, including labor and travel, replacement parts and consumables, software revisions, and preventative maintenance. Its RainStorm technology serves various biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection. The company was founded in 2004 and is headquartered in Lexington, Massachusetts.
Iroko Pharmaceuticals is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Philadelphia, PA.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
United Allergy Labs is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.